CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.

@article{Collins2015CD4DA,
  title={CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.},
  author={Sarah E. Collins and Marc Antoine Jean Juste and Serena P Koenig and Rode Secours and Oksana Ocheretina and Daphn{\'e} Bernard and Cynthia Riviere and Mike Calnan and Allison M. Dunning and Sandra M Hurtado R{\'u}a and Warren D. Johnson and Jean William Pape and Daniel W. Fitzgerald and Patrice D Severe},
  journal={The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease},
  year={2015},
  volume={19 1},
  pages={50-7}
}
SETTING Port-au-Prince, Haiti. OBJECTIVE To determine long-term effects of early vs. delayed initiation of antiretroviral therapy (ART) on immune recovery and tuberculosis (TB) risk in human immunodeficiency virus (HIV) infected individuals. DESIGN Open-label randomized controlled trial of immediate ART in HIV-infected adults with CD4 counts between 200 and 350 cells/mm(3) vs. deferring ART until the CD4 count was <200 cells/mm(3). The primary comparisons were CD4 counts over time and risk… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS